April 14, 2026Johnson & Johnson Officially Releases Q1 2026 Financial Report. Total Group Sales for the Period$24.062 billion, a year-on-year increase of 9.9%.

Among them,MedTech Sector Achieves Sales of $8.636 Billion, Up 7.7% Year-on-Year, with Operational Growth of 4.6%, becoming one of the core engines driving Johnson & Johnson's overall growth.

Thanks to better-than-expected performance in the first quarter, Johnson & Johnson directlyRaise the 2026 Full-Year Performance Outlook: Full-year sales are expected to reach$100.8 billion(Midpoint), a year-on-year increase of 7.0%; adjusted earnings per share of $11.55, a year-on-year increase of 7.1%, steadily advancing towards the long-term goal of "double-digit growth by the end of 2030."

As the global medical device industry enters a new phase of "innovation-driven, structural upgrade, and accelerating replacement by domestically produced products," Johnson & Johnson MedTech's performance in the first quarter not only demonstrates the robust resilience of a global leader in medical devices but also more clearly outlines...Cardiovascular, Surgery, Ophthalmology, OrthopedicsThe future trends of the four major golden tracks hold significant directional importance for China's high-end medical device market.

In Q1 2026, Johnson & Johnson MedTech achieved sales$8.636 billion, a year-on-year increase of 7.7%; excluding mergers and acquisitions, asset divestitures, and currency fluctuations, adjusted operational growth was 4.7%, continuing the strong recovery momentum since 2025.

By region:

• U.S. Market：Sales revenue reached 4.459 billion US dollars, increasing by 5.9% year-on-year, maintaining a steady foundation;
• International Market：Sales reached $4.177 billion, a significant year-on-year increase of 9.7%, outperforming the U.S. domestic market.
• Exchange Rate Contribution: Global exchange rate fluctuations brought a positive impact of 3.1 percentage points to MedTech, demonstrating Johnson & Johnson's global layout and risk resistance capability.

From the perspective of business structure, Johnson & Johnson MedTech has formedCardiovascular as the Core, Orthopedics as the Cornerstone, Surgery and Ophthalmology Growing RapidlyThe four-wheel drive pattern.

Q1, Johnson & JohnsonCardiovascular Business Becomes MedTech's First Growth Curve, achieving strong growth in the three major fields of electrophysiology, mechanical circulatory support, and intravascular lithotripsy (IVL).

Electrophysiology Business: Continuous High Growth, Innovative Products Scaling Up

Electrophysiology business continues strong performance, with global sales growing by double digits year-over-year. This quarter, Johnson & Johnson officially launched in Europe.VARIPULSE ProPulse Field Ablation System: New pulse sequence speeds up 5 times, significantly shortening operation time, further strengthening the leading advantage in the field of atrial fibrillation ablation.

Abiomed: Mechanical Circulatory Support (MCS) Maintains High Growth

ImpellaThe clinical penetration rate of a series of cardiogenic shock support devices continues to increase in scenarios such as acute myocardial infarction, high-risk PCI, and perioperative heart failure, with synchronized growth in the U.S. and international markets.

Shockwave Medical: Explosive Growth of IVL

ShockwaveContinued explosive growth, with global adoption of peripheral and coronary IVL products, becoming one of the preferred solutions for interventional treatment of calcified lesions. Shockwave IVL has become the "gold standard" for complex calcified lesions.

In Q1 2026, Johnson & Johnson's orthopedics business returned to steady growth after continuous optimization and restructuring:

• Trauma Business: Significant year-on-year growth globally, becoming the primary growth driver in orthopedics;
• Joint Business：Stable growth in hip and knee products, with international market growth rates higher than those in the U.S.;
• Spine and Sports Medicine: Remain stable, with structural adjustments continuing to advance.

Johnson & Johnson is advancing the strategic optimization of its orthopedics business, focusing onHigh-value consumables, minimally invasive tools, intelligent navigation, robotic assistanceHigh value-added fields, gradually exiting the low-margin, low-growth ordinary consumables track.

Johnson & Johnson's surgical business achieved steady growth in the first quarter in China.High-end staplers, ultrasonic scalpels, energy platforms, sutures, endoscopic instruments...core categories remain globally leading.

Currently, Johnson & Johnson Medical is transitioning from a single consumables supplier toMinimally Invasive Surgery Total Solution ProviderTransformation, Focus on Efforts:

• High-end Laparoscopic Staplers and Energy Devices
• Surgical Robot Ecosystem Collaboration
• Popularization of Disposable High-End Consumables
• Digital Surgical Assistance System

TECNIS PureSee New Artificial Lens Officially Receives FDA Approval, providing cataract patients with better contrast vision and extended depth of focus, further solidifying its leading position in the premium refractive intraocular lens market.

Cardiovascular Track: Three Major Trends Established - IVL, Electrophysiology, and Heart Failure Management

• China's Calcified Lesion Treatment (IVL) Sector to Enter Boom Period
• Chinese companies are speeding up their catch-up efforts, with Huitai, MicroPort, Xinmai, and Jianshi Medical all making strategic moves.
• Foreign and Domestic Products to Shift from "Direct Competition" to "Tiered Competition"

Orthopedics Track: Domestic Substitution Enters Deep Waters

Stable Market Landscape for Trauma Consumables in China After Centralized Procurement, China-produced leading products have already possessed global competitiveness. In the future, joints and spine will continue to...Minimally Invasive, Intelligent, and RoboticUpgrade.

Surgical Track: High-end Staplers, Endoscopes, and Energy Instruments Become the Main Battlefield

Johnson & Johnson Surgical adheres to a high-end route, which meansLow-price internal competition is not sustainableChinese enterprises must shift towards precision manufacturing, self-developed energy platforms, and integrated minimally invasive solutions.

Imported and Domestic: From Competition to Synergy

The future of China's medical device market will be:

• Foreign Capital Stays at the High-end, Innovation Takes the Lead
• Made in China Expands at the Grassroots Level, Cost-Effectiveness Breakthrough
• Platform enterprises rise rapidly, completing the whole industry chain

The Ultimate Trend in the Industry: Innovation Determines Everything

Medical devices have enteredInnovation Reigns SupremeTimes, the future winners must possess:

• Continuous R&D Capability
• Precision Manufacturing Capability
• Global Clinical Evidence
• Strong Compliance System

Johnson & Johnson's 7.7% High Growth in MedTech for Q1 2026: More Than Just a Stellar Earnings ReportGlobal Medical Device Industry Strategy Guide。

Cardiovascular breakthroughs, orthopedic recovery, surgical upgrades, and ophthalmic innovations clearly indicate the four major directions for future growth. Meanwhile, in the Chinese market, foreign enterprises are accelerating innovation, domestically produced products are rapidly breaking through, and platform-based companies are integrating ecosystems, marking the beginning of a significant transformation.High Quality, Innovation-Driven, Long-Term OrientedA new era of medical devices has arrived. For Chinese companies, catching up is no longer distant, surpassing is happening now.